Wednesday, February 17, 2021 1:55:16 PM
An EUA is not going to happen. Trials have a lot of secondary endpoints. Having one subset of patients meeting one secondary endpoint is a nothing burger. Almost all trials will show benefit to a small group in one secondary endpoint if you slice and dice the groups enough. The amount of patients showing benefit in this trial is so tiny that it borders on irrelevant. At best, the trial will be expanded and the primary endpoint changed. As is, the trial is meaningless.
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM